EGFR外显子18 DelE709_T710insD作为晚期EGFR外显子18 E709H肺腺癌对阿法替尼获得性耐药的机制 - Suppr

EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.

作者信息

Zeng Liang, Zhang Yongchang, Yang Nong

机构信息

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, People's Republic of China.

出版信息

J Thorac Oncol. 2018 Jun;13(6):e93-e95. doi: 10.1016/j.jtho.2018.01.006.

DOI:10.1016/j.jtho.2018.01.006

PMID:29793651

Abstract

摘要

相似文献

EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.

J Thorac Oncol. 2018 Jun;13(6):e93-e95. doi: 10.1016/j.jtho.2018.01.006.

Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.

Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.

EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.

Lung Cancer. 2017 Jun;108:45-47. doi: 10.1016/j.lungcan.2017.02.023. Epub 2017 Mar 1.

Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.

J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.

A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.

J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.

Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18.

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.

J Thorac Oncol. 2018 Aug;13(8):1222-1226. doi: 10.1016/j.jtho.2018.04.012. Epub 2018 Apr 24.

Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.

J Thorac Oncol. 2019 Oct;14(10):e220-e221. doi: 10.1016/j.jtho.2019.05.023.

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.

Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10.

引用本文的文献

A Lung Adenocarcinoma Patient With a Rare E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review.

Front Oncol. 2021 Jun 11;11:700345. doi: 10.3389/fonc.2021.700345. eCollection 2021.

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors.

Cancers (Basel). 2018 Nov 13;10(11):434. doi: 10.3390/cancers10110434.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献